Abstract

Objective: To evaluate the efficacy of catumaxomab treatment for malignant ascites.
Cases: Four patients with malignant ascites who required paracentesis once or more a week and were considered for catumaxomab treatment, received catumaxomab following the therapeutical paracentesis, via intraperitoneal port catheter on the day 0., 3., 7. and 10. The frequency of paracentesis need and before and after the treatment wee compared and it was found that this frequency was decreased in each of the patients.
Conclusion: Catumaxomab therapy can be a good choice of treatment for the patients who suffer from malignant ascites and must be considered to improve particularly these patients’ quality of lives.

Key words: Catumaxomab, malignant ascites, palliative care